by Eric Christianson | Aug 30, 2026 | Psychiatry and Addiction Medication and Disease State Clinical Pearls
Naltrexone and acamprosate are two commonly used medications for alcohol use disorder (AUD), but the ideal candidate for each medication is different. I will discuss the most important clinical practice pearls and nuggets that will likely show up on your board exam...
by Eric Christianson | May 31, 2026 | Endocrine Medication and Disease State Clinical Pearls
Weight loss medications can differ substantially in efficacy, adverse effect profiles, and monitoring considerations, making patient-specific counseling essential. In this blog post, I share common practice pearls for weight loss medications. GLP-1 Type Agents Slow...
by Eric Christianson | Nov 3, 2024 | Psychiatry and Addiction Medication and Disease State Clinical Pearls
There are two agents that are frequently used in alcohol use disorder. Acamprosate and naltrexone have distinct advantages and disadvantages in the treatment of alcohol use disorder. In this article, we will compare the clinical benefits and risks of acamprosate vs...
by Eric Christianson | Dec 13, 2023 | Psychiatry and Addiction Medication and Disease State Clinical Pearls
Alcohol use disorder can be managed with medications. American Psychiatric Association Guidelines recommend acamprosate or naltrexone as a first-line agent for moderate to severe management of alcohol use disorder. In this article, I will compare acamprosate versus...
by Eric Christianson | Mar 3, 2021 | Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
Obesity is a major risk factor for many comorbidities (hypertension, dyslipidemia, osteoarthritis, sleep apnea, heart disease, type 2 diabetes) and increases all-cause and cardiovascular mortality. With over 40% of Americans qualifying as obese (body mass index ≥30...
